NCT03331848View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 15, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

February 1, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Placebo oral capsule

BID

DRUG

PXT002331 - 20mg

Oral

Sponsors
All Listed Sponsors
lead

Prexton Therapeutics

INDUSTRY